W. Garvey to Fructose
This is a "connection" page, showing publications W. Garvey has written about Fructose.
Connection Strength
2.312
-
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
Score: 0.545
-
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
Score: 0.456
-
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014 Apr; 37(4):912-21.
Score: 0.426
-
Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013 Sep; 12(5):741-56.
Score: 0.416
-
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.
Score: 0.375
-
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
Score: 0.093